Canadian cannabis cultivator and manufacturer Organigram Holdings plans to consolidate its shares on a 4-to-1 basis in order to maintain its U.S. equity listing on the Nasdaq exchange.
Nasdaq warned Organigram in January that its share price had fallen below the exchange’s $1 minimum bid price requirement for 30 consecutive days, risking possible delisting.
ADVERTISEMENT
Organigram’s shares have lost value since then, opening at $0.40 on the Nasdaq on Wednesday.
The share consolidation is also meant to “reduce volatility and to enhance the marketability of the common shares to institutional investors,” Organigram in a news release.
The reverse share split is expected to take place July 7 and will also affect Organigram’s shares listed on the Toronto Stock Exchange (TSX) in Canada.
Both exchanges must approve the consolidation.
Organigram isn’t the only cannabis company to face issues complying with stock exchange requirements.
Hexo Corp. consolidated its
Read full article on Marijuana Business Daily
